| Literature DB >> 455312 |
M P Corder, T E Elliott, L C Maguire, J T Leimert, S K Panther, P A Lachenbruch.
Abstract
A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7--19+ weeks' duration. The usual time to the occurrence of a greater than 25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.Entities:
Mesh：
Substances：
Year: 1979 PMID： 455312
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960